Balancing medicine prices and business sustainability: analyses of pharmacy costs, revenues and profit shed light on retail medicine mark-ups in rural Kyrgyzstan by Waning, Brenda et al.
Waning et al. BMC Health Services Research 2010, 10:205
http://www.biomedcentral.com/1472-6963/10/205
Open Access RESEARCH ARTICLE
© 2010 Waning et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Research article Balancing medicine prices and business 
sustainability: analyses of pharmacy costs, 
revenues and profit shed light on retail medicine 
mark-ups in rural Kyrgyzstan
Brenda Waning*1,2, Jason Maddix1 and Lyne Soucy3
Abstract
Background: Numerous not-for-profit pharmacies have been created to improve access to medicines for the poor, but 
many have failed due to insufficient financial planning and management. These pharmacies are not well described in 
health services literature despite strong demand from policy makers, implementers, and researchers. Surveys reporting 
unaffordable medicine prices and high mark-ups have spurred efforts to reduce medicine prices, but price reduction 
goals are arbitrary in the absence of information on pharmacy costs, revenues, and profit structures. Health services 
research is needed to develop sustainable and "reasonable" medicine price goals and strategic initiatives to reach 
them.
Methods: We utilized cost accounting methods on inventory and financial information obtained from a not-for-profit 
rural pharmacy network in mountainous Kyrgyzstan to quantify costs, revenues, profits and medicine mark-ups during 
establishment and maintenance periods (October 2004-December 2007).
Results: Twelve pharmacies and one warehouse were established in remote Kyrgyzstan with < US $25,000 due to 
governmental resource-sharing. The network operated at break-even profit, leaving little room to lower medicine 
prices and mark-ups. Medicine mark-ups needed for sustainability were greater than originally envisioned by network 
administration. In 2005, 55%, 35%, and 10% of the network's top 50 products revealed mark-ups of < 50%, 50-99% and 
> 100%, respectively. Annual mark-ups increased dramatically each year to cover increasing recurrent costs, and by 
2007, only 19% and 46% of products revealed mark-ups of < 50% and 50-99%, respectively; while 35% of products 
revealed mark-ups > 100%. 2007 medicine mark-ups varied substantially across these products, ranging from 32% to 
244%. Mark-ups needed to sustain private pharmacies would be even higher in the absence of government subsidies.
Conclusion: Pharmacy networks can be established in hard-to-reach regions with little funding using public-private 
partnership, resource-sharing models. Medicine prices and mark-ups must be interpreted with consideration for 
regional costs of business. Mark-ups vary dramatically across medicines. Some mark-ups appear "excessive" but are 
likely necessary for pharmacy viability. Pharmacy financial data is available in remote settings and can be used towards 
determination of "reasonable" medicine price goals. Health systems researchers must document the positive and 
negative financial experiences of pharmacy initiatives to inform future projects and advance access to medicines goals.
Background
Much of the developing world still lacks access to essen-
tial medicines. Most people in developing countries seek
care and medicines from private sector pharmacies, even
before seeking care at a clinic or hospital [1]. Health sys-
tems research must include assessment of pharmacy
interventions designed to increase access to medicines
given the dominant role pharmacies play in health service
delivery.
Access to essential medicines in low resource settings is
hindered by high and unaffordable medicine prices [2-7],
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and global calls to make medicines more affordable have
increased in recent years. The Millennium Development
Goals include a target that aims "in cooperation with
pharmaceutical companies, [to] provide access to afford-
able essential drugs in developing countries" [8]. The Mil-
lennium Development Task Force specifically
recommends that countries "seek ways to reduce the
trade and distribution mark-ups on prices of essential
medicines and to ensure availability of essential medi-
cines in public health care facilities" [8]. The Working
Group on Access to Essential Medicines established by
the United Nations Millennium Project suggested that
generic competition, price negotiation, differential pric-
ing, and effective procurement are the four strongest
levers to reduce medicine prices [9].
[10] (delete). The World Health Organization (WHO)
and Health Action International (HAI) recently released a
methodology to measure medicine price components
along the supply chain [11]. The new module is designed
to identify where "add-on" prices are applied throughout
the supply chain from manufacturer to patient, including
duties, taxes, tariffs, and mark-ups [11]. A recent synthe-
sis of WHO/HAI medicine price surveys revealed average
retail mark-ups on medicines ranging up to 552% [3],
while another summary reported excessive mark-ups
specifically in the private sector [11]. These results are
compelling and useful for advocates who pressure policy
makers to intervene to bring about lower prices. But
when confronted with survey results, Ministers of Health
inevitably ask: "What is a reasonable mark-up for medi-
cines?" This question has yet to be answered. Indeed, the
authors of the WHO/HAI synthesis themselves note that
additional research is required to determine appropriate
medicine mark-ups that are not only reasonable, i.e. as
affordable to the consumer as possible, but also ensure
the economic viability of the supply chain [3]. This paper
is the first publication to respond to this call.
Medicine prices and mark-ups will be difficult to inter-
pret without some basic understanding of the cost, reve-
nue, and profit structures of pharmacy businesses. To
remain viable, a pharmacy must be able to recoup its
costs and make some minimal profit. While numerous
small- and large-scale pharmacies and pharmacy net-
works have been created to improve access to medicines
for the poor [12-32], many have failed due to non-existent
or poor quality business plans and financial planning
[29]. Health services research, however has failed to pro-
vide details of how and why these pharmacy initiatives
failed. Organizations and governments will continue to
open pharmacies as a means of increasing access to med-
icines. But, until the financial and managerial success and
failures of these initiatives are documented, lessons
learned from previous experiences will be lost, the same
mistakes will be repeated, and pharmacies will continue
to fail.
Health services research is also needed to determine
medicine prices that not only advance access goals
through affordability but also provide incentives for own-
ership and management of pharmaceutical enterprises.
While affordability is a key determinant of access to med-
icines, downward pressure on prices to unsustainable lev-
els can actually threaten access by removing incentives
for entrepreneurs to own and operate pharmacies, there-
fore making pharmacies less geographically accessible to
consumers. Striking a balance between the availability of
medicines and the sustainability of pharmacies is critical,
given that the majority of people in developing countries
rely on the private sector for essential medicines [1]. This
balance becomes even more tenuous in rural regions
where population densities are low, pharmacies are scarce
or nonexistent, residents have little money, and the few
available medicines are expensive. In Kyrgyzstan, more
than 80% of the country is covered by mountains and 64%
of people live in rural regions [33].
The purpose of this study is to quantify the cost and
revenue structures for establishing and maintaining rural
pharmacies in Kyrgyzstan and to examine medicine
mark-ups to determine if they can be further reduced
without jeopardizing the sustainability of these enter-
prises. In so doing, we provide the first example of how
cost accounting methods can be applied to pharmacy
financial data to ascertain "reasonable" medicine price
and mark-ups. Given the demand for this type of infor-
mation by researchers [3] and national policy makers, we
provide guidance on expanding and replicating this
research to advance and support future access to medi-
cines initiatives.
Methods
For this case study, we applied cost accounting methods
to information obtained from a not-for-profit rural phar-
macy network to quantify cost, revenue, profit and medi-
cine mark-ups from 2004 to 2007. The retail network is
located in Jumgal District of Naryn Province in Kyrgyz-
stan. Jumgal, like most of Kyrgyzstan, is mountainous,
but one of the the most accessible mountainous region to
the capital city of Bishkek. The retail network, compris-
ing 12 pharmacies and one warehouse, is managed by a
local non-governmental organization (NGO) and oper-
ated under a revolving medicine fund mechanism. Estab-
lished in late 2004 in collaboration with the Kyrgyzstani
government, the network was designed specifically to
increase access to high quality, affordable medicines in
rural villages lacking access to pharmacy outlets. The net-
work is described in detail elsewhere [34].Waning et al. BMC Health Services Research 2010, 10:205
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Pharmacy network costs
We estimated start-up costs (expenses incurred in estab-
lishing the network) and recurrent costs (ongoing costs
associated with maintaining the network). We distinguish
between fixed recurrent costs - costs that are indepen-
dent of business volume - and variable recurrent costs -
costs that fluctuate depending upon business volume.
Examples of fixed recurrent costs include salaries, insur-
ance payments, utilities, and travel from the central office
to the region for medicine deliveries. Variable recurrent
costs included office supplies, repairs, taxes, nurse-dis-
penser bonuses, and travel between the warehouse and
pharmacies. Cost information was obtained from docu-
ments such as purchase receipts, payment invoices, and
inventory reports.
While non-product costs to support the central office,
warehouse, and each pharmacy could be easily tracked,
costs for product purchases were only available for the
network as a whole and could not be allocated directly to
individual pharmacies.
Pharmacy network revenues
Pharmacy revenues are limited to income from the sale of
products, namely medicines and sundries. Monthly reve-
nue reports for individual pharmacies were provided by
the central NGO administration. While inventory infor-
mation was available on medicine flow through the cen-
tral office, warehouse, and individual pharmacies, the
pharmacies did not keep detailed sales records.
Pharmacy network profit
Profit is presented for both the network as a whole and
for individual pharmacies within it.
Network profit is calculated on a monthly basis as fol-
lows:
Individual pharmacy profit is estimated on a monthly
basis as follows:
where
This estimation assigns the costs to maintain the cen-
tral office and warehouse equally across each of the 12
pharmacies. In the absence of pharmacy-specific product
purchase and sales records, it also estimates pharmacy-
specific monthly product costs as a function of individual
pharmacy revenue.
Medicine mark-ups
The pharmacy network was established in September
2004 and it took a few months to build up sufficient
inventory to meet local demand. We, therefore, selected
the 50 most profitable products over the 2005-2007 time
period. We then calculated mark-ups for these top 50
products in each of the study years (2004, 2005, 2006,
2007). Mark-ups for these products were calculated by
ear as follows:
Calculations for medicine mark ups utilize warehouse
level records for products distributed to pharmacies in a
given month.
All cost and revenue estimates are provided in Kyrgyz
Som (KGS), although start-up costs are converted to
United States (US) dollars to provide value context using
a conversion factor of 40 KGS per one US dollar.
Results
Pharmacy network start-up costs
The costs to establish the pharmacy network in late 2004
totalled 866,665 KGS (US $21,667), split almost equally
across medicine and non-medicine costs (Figure 1).
Building pharmacies and training staff accounted for 39%
and 25% of non-medicine costs, respectively, while estab-
lishing the warehouse and central office each accounted
for 18%.
In-kind donations from local Village Health Commit-
tees [35] and the Kyrgyz-Swiss Health Reform Support
Project also helped establish the network. Such donations
included materials and labour to refurbish the pharma-
cies and warehouse, and some pharmacy furniture (addi-
tional file 1).
Pharmacy network recurrent costs
Costs for wholesale product purchases vary according to
sales volumes in pharmacies. The more products sold by
pharmacies each month, the more products the central
staff need to purchase from wholesalers to replenish
pharmacy stock. As expected, product purchases com-
prise the largest portion of the variable recurrent costs
across all years (Figure 2). All non-product costs
increased annually as the newly formed business steadily
grew. Non-product variable costs increased 40% from
2005 to 2007, while fixed costs increased 54% from 2005
to 2007, largely due to increased salary expenses for cen-
tral administrative staff whose contributions were pro-
vided in-kind in the first year only. Recurrent cost
profit revenues costs network network network =−
profit revenue costs pharmacy i pharmacy i pharmacy i =−
costs non product costs
non costso
pharmacy i pharmacy i =+ -
-product f ffice and wharehouse product costs
revenuepharmacy i
network 12
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estimates for 2007 are the most accurate, reflecting the
realities of a "mature" network. In 2007, product variable
costs, non-product variable costs, and non-product fixed
costs comprise 70%, 12%, and 18% of total costs, respec-
tively.
Salaries for central office and warehouse staff represent
the greatest portion of non-medicine fixed costs. In 2007,
salaries and social insurance payments for employees
accounted for 58% and 24% of these costs, respectively
(table 1). Travel from Bishkek, the capital city and head-
quarters, accounted for 17% of fixed costs, and included
trips to the warehouse and to the pharmacies for medi-
cine deliveries. The supervisory trips from headquarters
were always combined with medicine deliveries to avoid
additional travel costs.
Nurse-dispenser bonuses, determined by product sales
volume, are the largest portion of non-product variable
costs, representing 75% of these costs in 2007 (table 1)
and averaging 634, 869, and 942 KGS per nurse per
month for 2005, 2006, and 2007, respectively. Transport
for travel between the warehouse and pharmacies, which
includes product deliveries, accounts for 15% of variable
costs in 2007.
Cost-sharing arrangements with the Kyrgyzstani Min-
istry of Health (MOH) allow for very low operating costs.
The MOH donated space within primary care clinics to
house the pharmacies, on hospital premises to establish
the warehouse, and in a Bishkek government building to
house the central office. Co-location of the pharmacy
network within government facilities means the phar-
macy network operates without paying rent or utilities,
with the exception of a very modest share of utilities in its
central office. In addition, the MOH pays the regular sala-
ries of the nurse-dispensers - who work principally as
practicing nurses in the co-located primary care clinics -
while the NGO pays the nurses a bonus for taking on the
Figure 1 Start-up costs to establish the pharmacy network.
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(US $10,824)
Figure 2 Overview of recurrent costs (KGS) for pharmacy network.
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additional task of operating the pharmacies. Whereas the
nurses' regular salaries are fixed and subsidized by the
Kyrgyz government, the bonuses paid by the NGO are
variable, based on pharmacy sales volume.
Pharmacy network revenues
Average monthly revenues increased from 82,837 KGS in
2005 to 121,438 KGS in 2007 (Figure 3). Monthly reve-
nues were highly erratic in the first two years of opera-
tion, likely due to inconsistent delivery of stock
replenishment to network pharmacies and seasonal vari-
ation of medicine use. By, 2007, however, deliveries and
revenues had become more stable.
Pharmacy network profit
Analyses reveal pharmacy network profits at approxi-
mately break-even levels over the entire study period.
After operating slightly below break-even levels in 2005,
the network averaged small positive profits in 2006 and
break-even profit levels in 2007 (Figure 4). Like monthly
revenues, monthly expenditures on products and
monthly profits were erratic.
Retail product mark-ups
Mark-ups vary substantially across the network's top 50
products (which account for >50% of network profits),
ranging from 32% to 244% in 2007. Those above 150%
that might be considered "excessive" cross-subsidize
lower mark-ups applied to other medicines. Upward
trends in retail mark-ups are noted for nearly all 50 top-
selling medicines and health products from 2004 to 2007.
Initial mark-ups were low in 2005, the first full year of
operation, with 27 (55%) and 17 (35%) products revealing
mark-ups of < 50% and 50-99%, respectively (Table 2).
Only five (10%) products had a mark-up greater than
100% in 2005. Mark-ups steadily increased from 2005 to
2007 as the NGO was unable to cover its operating costs
with the initial mark-ups. By 2007, only nine (19%) and 22
(46%) products revealed mark-ups of < 50% and 50-99%,
respectively; while 17 (35%) products showed mark-ups
greater than 100%. Mark-up trends for these specific
medicines and health products are provided in additional
file 2.
Discussion
This study demonstrates the utility of analyzing financial
data obtained from pharmacies to predict costs of estab-
lishing new pharmacy businesses and determine reason-
Figure 3 Monthly revenue and average monthly revenue by year of pharmacy network (KGS).
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Table 1: Detailed non-product recurrent costs (KGS) for 
pharmacy network
2005 2006 2007
Non-product fixed costs
Central office salaries (supervisors) 44,400 93,600 110,500
Warehouse salaries 39,710 35,835 38,582
Social insurance 45,602 54,557 61,856
Utilities 6,997 2,764 3,413
Travel from central office to region 30,077 12,936 42,588
Non-product variable costs
Office supplies, repair, other 16,230 4,917 15,271
Taxes 4,736 8,159 2,854
Nurse-dispenser bonuses 91,229 125,092 135,694
Travel between warehouse and 
pharmacies
17,431 26,730 27,390Waning et al. BMC Health Services Research 2010, 10:205
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able medicine prices and mark-ups that are affordable but
still ensure pharmacy viability. Information gained from
this type of research can empower policy makers and
advocates to develop strategic, evidence-based interven-
tions appropriate for their local context, without jeopar-
dizing sustainability of pharmacy enterprises and
availability of medicines.
Medicine mark-ups needed to ensure non-profit viability 
were higher than expected and might be considered 
"excessive" when interpreted without consideration for the 
cost of business
The level of medicine mark-up needed to sustain the
pharmacies was much greater than expected in the plan-
ning phase of the project. While the majority of medi-
cines revealed mark-ups of less than 50% upon the initial
establishment of the network, mark-ups increased
steadily year after year, with few medicines marked-up
below 50% and the vast majority marked-up well above
50% and 100% by the end of 2007.
High mark-ups were necessary even given the net-
work's reliance on government subsidies for rent, over-
head, and nurses' salaries, as well the in-kind
contributions of others. The network's high operating
costs for salaries and travel/transport, together with low
inventory turnover, translated into high carrying costs for
the pharmacy network. This is likely the case in many
other rural regions.
The pharmacy network has few options to lower medicine 
prices without jeopardizing availability
In order to lower some mark-ups that may be considered
"excessive" (e.g. >150%), the management would need to
increase mark-ups on other medicines. The NGO could
leverage medicine prices and mark-ups in an effort to
drive demand of specific products. Mark-ups could be
redistributed, applying low mark-ups to encourage the
use of key essential medicines and high mark-ups to dis-
courage the use of non essential medicines. Similarly, the
NGO should increase mark-ups on sundries (e.g. creams,
shampoos, etc.) to maximize revenues and cross-subsi-
dize lower mark ups on medicines. The NGO could also
conduct market surveys to identify additional sundries
held in high demand by the local community.
While we have not presented the analysis in this paper,
we found that profit at the individual pharmacy level var-
ied, with some pharmacies performing better than others
[36]. Not surprisingly, pharmacies located in villages with
Table 2: Retail mark-up trends for the 50 top-selling products*, 2004-2007
# of products per mark-up category
< 50% n (%) 50-99% n (%) 100-200% n (%) > 200% n (%)
2004 26 (74) 5 (14) 2 (6) 2 (6)
2005 27 (55) 17 (35) 3 (6) 2 (4)
2006 14 (29) 21 (44) 12 (25) 1 (2)
2007 9 (19) 22 (46) 15 (31) 2 (4)
*50 most profitable products 2005-2007. Not all products sold in all years.
Figure 4 Pharmacy network monthly profit and average monthly profit by year (KGS).
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larger populations enjoyed greater profits than those in
less-populated villages. Distance from the warehouse in
the district center was more closely related to profit, with
the most remote pharmacies operating at a slight loss. In
this mountainous region, remote pharmacies are located
45-66 kilometers (28-41 miles) from the warehouse.
Roads to many of these villages are unpaved and in disre-
pair, making travel time-consuming and costly, especially
during the region's long winters.
It is certainly possible to increase the operational effi-
ciency of these pharmacies, but potential gains would be
marginal and insufficient to reduce current medicine
prices and mark-ups. Closing pharmacies or reducing the
number and type of medicines stocked in villages operat-
ing at a loss would increase overall network profit, but at
the expense of decreasing access to medicines in the vil-
lages most in need. This option would directly contradict
the original intention of establishing the network to meet
the needs of the least served. Nurse dispenser bonuses
should be re-evaluated. Current compensation is based
upon sales volume and creates perverse incentives for
over-prescribing. These nurse dispenser bonuses account
for costs nearly equal to product costs and could be
reduced by revising compensation policies.
Results from analyses of not-for-profit pharmacies can be 
used to guide policy decisions in for-profit pharmacies
Medicine prices and mark-ups revealed in this study can
be used as reliable benchmarks to assess those applied to
medicines in for-profit pharmacies in similar regions of
Kyrgyzstan. Private sector pharmacies in this region
would need to apply even higher retail medicine mark-
ups in order to remain profitable in the absence of subsi-
dies. Private pharmacies need to recoup the costs of rent,
utilities, and salaries in addition to the costs we included
in our analysis of the subsidized, not-for-profit pharmacy
network. In addition, the start-up costs in the Kyrgyz
pharmacy network were paid up front by others, and
therefore, no amortization of these costs was needed;
however, private pharmacies would need to amortize
these up-front costs over several years. After accounting
for these additional costs, advocates can provide policy
makers with realistic, evidence-based goals for medicine
price determination that ensure the viability and sustain-
ability of pharmacy businesses.
Medicine markets in rural regions are local, requiring 
additional localized research with improved methods to 
better inform decision makers
While these results can be extrapolated to similar rural
regions in Kyrgyzstan, they cannot be extrapolated to
large cities or more remote regions in Kyrgyzstan or to
other low-resource countries. The supply and demand
sides of pharmaceutical markets, as well as the business
structures of pharmacies, vary dramatically within and
across countries. Sound policy decisions can only be
made after understanding the unique characteristics of
local markets and pharmacy businesses. For example, a
WHO/HAI survey in Syria reports a fixed price system
whereby retail pharmacies apply maximum medicine
mark-ups of 8% for more expensive medicines to 30% for
less expensive medicines [37]. If this pricing system was
adopted by Kyrgyzstan, the rural pharmacies would fail to
thrive and there would be no incentive to open new phar-
macies in regions without them. Price controls are often a
knee-jerk governmental reaction to high and unafford-
able medicine prices; but without understanding local
cost of business, imposing arbitrary price and mark-up
limitations could jeopardize the availability of medicines
and market growth, especially in rural regions.
Our study also revealed the importance of using sam-
pling methods based upon local medicine use patterns.
We based our selection of medicines in this study upon
sales volume, rather than a pre-determined basket of
medicines, to ensure we are measuring prices and mark-
ups for medicines that are actually used in the local con-
text. While several hundred items were purchased by the
network over the study period, we chose the top selling
50 products because their sales represent more than 50%
of all revenues. The top-selling 50 products in terms of
profit and volume of sales are similar and represent those
products in regular demand while the remaining prod-
ucts are typically purchased only a few times over the
entire period. Researchers might consider replicating
studies such as ours using volume-based sampling and
the local not for profit prices as reference prices.
Research on medicine mark-ups often uses summary
measures (such as the average mark-up) across all or a
select basket of medicines. Our study found higher mark-
ups applied to the more commonly purchased medicines,
underscoring the importance of selecting medicines
based upon local demand. In addition, we revealed dra-
matic and unpredictable variation in mark-ups applied
across the top selling products, illustrating the limited
utility of summary measures and the need to provide
detailed results for the entire distribution of medicine
mark-ups.
We recognize that it is difficult to obtain financial data
on cost of doing business, given the proprietary nature of
this information. But we believe this information is avail-
able, since most countries have pharmacy networks
owned and operated by NGOs or other non profit enti-
ties. Typically, these organizations are in the pharmacy
business in order to provide quality and affordable medi-
cines to the poor and would likely share their financial
information in the interest of national efforts to increase
access to medicines. Projects such as the MedicinesWaning et al. BMC Health Services Research 2010, 10:205
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Transparency Alliance are in a good position to obtain
and use this type of information to inform policy, given
their multi stakeholder and country-led approaches [38].
Study limitations
Our study contributes to the growing body of literature
on medicine prices, but it has limitations. We had full
access to all financial data but expect we missed some
unaccounted costs, such as "informal payments" to
inspectors, as well as other undocumented revenues. We
measure mark-ups at retail level only. The determination
of cost of business and mark-up at manufacturer and
wholesale level would provide a more comprehensive
view of the market, but we had no access to such data.
Because pharmacies did not record medicine-specific
sales or information on product losses (e.g., unpaid cus-
t o m e r  b i l l s ,  t h e f t ,  e x p i r a t i o n ,  e t c . ) ,  w e  w e r e  u n a b l e  t o
assess product-specific revenues and costs associated
with low turnover. In the absence of pharmacy-specific
purchase information, we were unable to measure
directly recurrent medicine costs at the pharmacy level.
Instead, we estimated these costs as a function of individ-
ual pharmacy revenue.
There is no evidence to suggest wholesalers engaged in
rebate and bundling practices that are common in devel-
oped countries [39,40]. Finally, we present current medi-
cine prices in lieu of adjusting prices for inflation after
noting that most medicine prices outside the pharmacy
network trended downward or remained unchanged over
the four years [34,36] and did not seem to follow the over-
all national inflation rate of 10% [41].
Conclusion
Running pharmacy businesses in rural regions is costly,
requiring high medicine mark -ups to recoup opera ting
costs and maintain inventory with low turnover. Our
study revealed high medicine mark-ups were needed to
sustain not-for-profit pharmacies even in the presence of
government subsidies and cost-sharing arrangements.
Few options to lower medicine prices are available when
pharmacies are operating at break-even or low profit lev-
els, but might include interventions to increase opera-
tional efficiency; decrease stock levels in low-volume
outlets; and redistribute low mark-ups to encourage the
use of key essential medicines and high mark-ups to dis-
courage the use of non-essential medicines.
Survey results detailing medicine prices and mark-ups
have limited utility without an understanding of regional
pharmacy cost, revenue, and profit structures such as
those we observed in this study. Policy makers and advo-
cates need this context to set realistic and non-arbitrary
goals to reduce medicine prices and mark-ups.
Because medicine prices and mark-ups are locally
determined, this type of analysis will need to be repli-
cated in other regions to better inform local and national
policies and strategies aimed to increase access to medi-
cines. Interventions must be designed and evaluated to
carefully balance medicine prices with pharmacy busi-
ness sustainability to ensure the availability of medicines
in rural regions.
Funding
United States Agency for International Development
through the Child and Family Applied Research Project at
the Boston University School of Public Health.
Additional material
Competing interests
The authors declare they have no competing interests.
Authors' contributions
BW designed and coordinated the study, participated in data cleaning and
data analysis, and was the lead author on this paper. JM coordinated data col-
lection and management, conducted data analysis, and participated in prepa-
ration of the manuscript. LS assisted in data analysis and preparation of the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
The authors thank Damira Bibosunova, Neal Brandes, Mariam Djankorozova, 
Heather Haberle, Zina Hazeeva, Ainura Ibraimova, Melitta Jakab, Elizabeth Lun-
deen, and Tobias Schuth for their contributions and support in the design and 
conduct of the study. We thank Lucy Honig and Bert Leufkens for their com-
ments and edits on the paper. We also thank the reviewers for their thoughtful 
comments.
Author Details
1Boston University School of Medicine, Department of Family Medicine; One 
Boston Medical Center Place, Dowling 5 South, Boston, MA 02118, USA, 
2Utrecht University, Utrecht, Netherlands and 3Partners in Health, Boston, MA, 
USA
References
1. World Health Organization: World Medicines Situation.  Geneva; 2010 in 
press. 
2. Babar ZUD, Ibrahim MIM, Singh H, Bukahri NI, Creese A: Evaluating drug 
prices, availability, affordability, and price components: implications 
for access to drugs in Malaysia.  PLoS Med 2007, 4(3):0466-0475.
3. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R: Medicine prices, 
availability, and affordability in 36 developing and middle-income 
countries: a secondary analysis.  Lancet 2009, 373(9659):240-249.
4. Gelders S, Ewen M, Noguchi N, Laing R: Price, availability and 
affordability: An international comparison of chronic disease 
medicines.  Cairo: World Health Organization Regional Office for the 
Eastern Mediterranean and Health Action International; 2006. 
5. Mendis S, Fukino K, Cameron A, Laing R, Filipe A Jr, Khatib O, Leowski J, 
Ewen M: The availability and affordability of selected essential 
Additional file 1 Detailed break-down of one-time costs to establish 
the pharmacy network. Itemized costs (in USD and Kyrgyz Som) for all 
products and services needed to establish the pharmacy network.
Additional file 2 Trends in average retail mark-ups for 50 top-selling 
products 2005-2007*. Initial (2004) and average annual percent mark-ups 
(2005-2007) for the top 50-selling products. *medicines are tablets/cap-
sules unless otherwise noted. †products appear twice representing differ-
ent pack sizes procured for each product.
Received: 4 April 2010 Accepted: 13 July 2010 
Published: 13 July 2010
This article is available from: http://www.biomedcentral.com/1472-6963/10/205 © 2010 Waning et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. BMC Health Services Research 2010, 10:205Waning et al. BMC Health Services Research 2010, 10:205
http://www.biomedcentral.com/1472-6963/10/205
Page 9 of 9
medicines for chronic diseases in six low- and middle-income 
countries.  Bull World Health Organ 2007, 85:279-288.
6. Russo G, McPake B: Medicine prices in urban Mozambique: a public 
health and economic study of pharmaceutical markets and price 
determinants in low-income settings.  Health Policy Plan 2010, 
25(1):70-84.
7. Coghlan R, Auton M, M M: Supply chain and price components of 
antimalarial medicines: Uganda 2007.  Edited by: Reza J, Banerji J. 
Geneva: Medicines for Malaria Venture; 2008. 
8. Millenium Development Goal Gap Task Force: Delivering on the Global 
Partnership of Achieving the Millenium Development Goals: Millenium 
Development Goal 8.  New York: United Nations; 2008. 
9. Leach B, Paluzzi JE, Munderi P: Prescription for healthy development: 
increasing access to medicines.  London 2005.
10. Health Action International Medicine Prices   [http://www.haiweb.org/
medicineprices/]
11. World Health Organization and Health Action International: Measuring 
medicine prices, availability, affordability and price components.  2nd 
edition. Geneva; 2008. 
12. Sambo MN, Lewis I, Sabitu K: Essential drugs in primary health centres of 
north central Nigeria; where is Bamako initiative?  Nigerian J Clin Practice 
2008, 11(1):9-13.
13. von Massow F, Korte R, Cheka C, Kuper M, Tata H, Schmidt-Ehry B: 
Financially independent primary health care drug supply system in 
Cameroun.  Trop Med Int Health 1998, 3(10):788-801.
14. Murakami H, Phommasack B, Oula R, Sinxomphou S: Revolving drug 
funds at front-line health facilities in Vientiane, Lao PDR.  Health Policy 
Plan 2001, 16(1):98-106.
15. McPake B, Hanson K, Mills A: Community financing of health care in 
Africa: An evaluation of the Bamako initiative.  Soc Sci Med 1993, 
36(11):1383-1395.
16. United Nations Children's Fund: Equity of access in the implementation 
of the Bamako initiative: research on the Bamako initiative in Vietnam.  
Hanoi, Vietnam: United Nations Children's Fund; 1994. 
17. Hardeman W, Van Damme W, Van Pelt M, Por I, Kimvan H, Meessen B: 
Access to health care for all? User fees plus a Health Equity Fund in 
Sotnikum, Cambodia.  Health Policy Plan 2004, 19(1):22-32.
18. Hamada A: Essential drug revolving fund programme within the 
context of pharmaceutical development of Vietnam.  Programme: 
Evaluation of Nippon Foundation Drug Revolving Fund Project in Asia; 
1999. 
19. Ali GKM: How to establish a successful revolving drug fund: the 
experience of Khartoum state in the Sudan.  Bull World Health Organ 
2009, 87(2):139-142.
20. Ali GKM: Accessibility of medicines and primary health care: The impact 
of the revolving drug fund in Khartoum State.  Afr J Pharma Pharmaco 
2009, 3(3):70-77.
21. Svhakhang L, Sengaloundeth S, Freudenthal S, Walhstrom R: Availability 
of essential drugs and sustainability of village revolving drug funds in 
remote areas of Lao PDR.  In Health and Social Protection: Experiences from 
Cambodia, China and Lao PDF 23rd edition. Edited by: Meessen B, Pei X, 
Criel B, Bloom G. Antwerp: ITGPress; 2008:519-543. 
22. Umenai T, Narula IS: Revolving drug funds: a step towards health 
security.  Bull World Health Organ 1999, 77(2):167-171.
23. Huff MA, Rizal A: 20 Years of Revolving Drug Funds: Should the public 
sector conduct business?  In Public Health and Human Rights: APHA 134th 
Annual Meeting and Exposition Boston, MA; 2006. 
24. Fiedler JL, Wight JB: Financing health care at the local level: the 
community drug funds of Honduras.  Int J Health Plan Manage 2000, 
15(4):319-340.
25. Diallo I, McKeown S, Wone I: Bamako boost for primary care.  World 
Health Forum 1996, 17(4):382-385.
26. Witter S: Achieving sustainability, quality and access: lessons from the 
world's largest revolving drug fund in Khartoum.  East Mediterr Health J 
2007, 13(6):1476-1485.
27. Uzochukwu B, Onwujekwe O: Healthcare reform involving the 
introduction of user fees and drug revolving funds: influence on health 
workers' behavior in southeast Nigeria.  Health Policy 2005, 75(1):1-8.
28. Africare Community Health and Partnerships Program: Drug Revolving 
Fund Supervisory Tool: a Job Aid for Supervisors.  Africare. Washington, 
D.C 2001.
29. Cross PN, Huff MA, Quick JD, Bates JA: Revolving drug funds: Conducting 
business in the public sector.  Soc Sci Med 1986, 22(3):335-343.
30. Turshen M: Reprivatizing pharmaceutical supplies in Africa.  J Public 
Health Policy 2001, 22(2):198-225.
31. Waddington C, Panza A: Ten questions to ask about revolving drug 
funds.  Trop Doct 1991, 21(2):50-53.
32. Gilson L, Kalyalya D, Kuchler F, Lake S, Oranga H, Ouendo M: Strategies for 
promoting equity: experience with community financing in three 
African countries.  Health Policy 2001, 58(1):37-67.
33. Central Intelligence Agency: World Fact Book.  Central Intelligence 
Agency; 2009. 
34. Waning B, Maddix J, Tripodis Y, Laing R, Leufkens H, Gokhale M: Towards 
equitable access to medicines for the rural poor: analyses of insurance 
claims reveal rural pharmacy initiative triggers price competition in 
Kyrgyzstan.  Int J Equity Health 2009, 8(1):43.
35. Formation of Village Health Committees   [http://cah.kg/en/
formation_of_village_health_committees/]
36. Waning B, Maddix J, Djankorozova M, Gokhale M, Winter M, Diedrichsen E, 
Jafarov A: Improving rural access to medicines in Kyrgyzstan: a view 
through the lenses of insurance, households, communities, and retail 
pharmacy business.  Boston: Boston University School of Medicine; 2009. 
37. World Health Organization and Health Action International: Syrian Arab 
Republic: medicine prices, availability, affordability, and price 
components.  Cairo: World Health Organization Regional Office for the 
Eastern Mediterranean; 2003. 
38. Medicines Transparency Alliance   [http://
www.medicinestransparency.org/]
39. Kalmanowitz S: Drug/technology bundling: Good for you?  Drug Topics 
2004, 148:24.
40. Frank RG: Prescription Drug Prices: Why Do Some Pay More Than 
Others Do?  Health Aff 2001, 20(2):115-128.
41. International Monetary Fund: World Economic Outlook Database.  
Washington DC 2009.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-6963/10/205/prepub
doi: 10.1186/1472-6963-10-205
Cite this article as: Waning et al., Balancing medicine prices and business 
sustainability: analyses of pharmacy costs, revenues and profit shed light on 
retail medicine mark-ups in rural Kyrgyzstan BMC Health Services Research 
2010, 10:205